BioInvent to Initiate P-I/IIa Study with BI-1206 in Combination with Merck's Keytruda (pembrolizumab) for Solid Tumors
Shots:
- In July’2019- Bioinvent reports the FDA’s acceptance of its IND application of BI-1206 + Keytruda combination therapy based on the preclinical data demonstrating that BI-1206 enhances anti-tumor immune responses in patients with solid tumors
- BioInvent will evaluate the combination therapy in P-I/IIa study in patients with an advanced solid tumor- prior treated with anti-PD1 or anti-PD-L1 antibodies
- BioInvent’s BI-1206 is an anti- FcγRllB antibodies- currently being investigated in non-Hodgkin lymphoma and chronic lymphocytic leukemia and has received FDA’s OD designation for mantle cell lymphoma in 2019
Click here to read full press release/ article
Ref: BioInvent | Image: Merck
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
